Retatrutide GLP-3 Vial 5mg by Omnix Peptides — research-grade vial

Retatrutide GLP-3 Vial

← All Retatrutide GLP-3 research

Retatrutide (development code LY3437943) is a synthetic, once-weekly triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors that has been the subject of peer-reviewed phase 1 and phase 2 randomized controlled trials published in The New England Journal of Medicine, The Lancet, and Nature Medicine, including investigations of body weight, glycemic control, and hepatic steatosis in adult human participants.

SKU: N/A Category:

Research goals: Metabolic & Weight

Description

Retatrutide (development code LY3437943) is a synthetic, once-weekly triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors that has been the subject of peer-reviewed phase 1 and phase 2 randomized controlled trials published in The New England Journal of Medicine, The Lancet, and Nature Medicine, including investigations of body weight, glycemic control, and hepatic steatosis in adult human participants.

In a 48-week phase 2 trial published in The New England Journal of Medicine, adults with obesity (without type 2 diabetes) receiving once-weekly subcutaneous retatrutide at the 12 mg amount achieved a least-squares mean body weight reduction of 24.2%, compared with 2.1% in the placebo group [1].

Published Research on Retatrutide

The following peer-reviewed studies are summarized below. Full citations and direct links to each publication appear in the References section. All studies described in this section were conducted in adult human participants. Retatrutide is currently in phase 3 development and has not received regulatory approval; the studies cited below are phase 1b and phase 2 trials.

Phase 2 Obesity Trial — Jastreboff et al., New England Journal of Medicine (2023)

Jastreboff and colleagues conducted a phase 2, double-blind, randomized, placebo-controlled trial of retatrutide in adults with obesity. The trial enrolled 338 adults with a body mass index of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related condition, excluding individuals with type 2 diabetes. Participants were randomized in a 2:1:1:1:1:2:2 ratio to once-weekly subcutaneous retatrutide at 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, over a 48-week treatment period.

The authors reported that retatrutide treatment for 48 weeks resulted in substantial reductions in body weight compared with placebo [1]. Least-squares mean percentage changes in body weight at week 48 were −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg), and −24.2% (12 mg), compared with −2.1% in the placebo arm. At the 4 mg amount, 92% of participants achieved at least 5% weight reduction, 75% achieved at least 10%, and 60% achieved at least 15%.

Read the full study: Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (NEJM 2023).

Phase 2 Type 2 Diabetes Trial — Rosenstock et al., The Lancet (2023)

Rosenstock and colleagues conducted a phase 2, randomized, double-blind, double-dummy, placebo-controlled and active-comparator-controlled, parallel-group trial of retatrutide in adults with type 2 diabetes. The trial enrolled 281 participants across 42 research and healthcare centers in the United States, randomized to once-weekly subcutaneous retatrutide (0.5, 4, 8, or 12 mg), once-weekly subcutaneous dulaglutide 1.5 mg (active comparator), or placebo, over a 36-week treatment period.

The authors concluded that retatrutide demonstrated clinically meaningful glucose-lowering and bodyweight-lowering efficacy in adults with type 2 diabetes [2]. At week 24, mean body weight reduction at the 12 mg amount was approximately 16.9%, with concentration-dependent reductions in HbA1c across all retatrutide arms compared with placebo and dulaglutide.

Read the full study: Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes (Lancet 2023).

MASLD Substudy — Sanyal et al., Nature Medicine (2024)

Sanyal and colleagues conducted a prespecified phase 2a substudy of the original phase 2 obesity trial, evaluating retatrutide in participants with metabolic dysfunction-associated steatotic liver disease (MASLD). Of the 338 participants in the main obesity trial, 98 met the inclusion criterion of 10% or greater liver fat content as measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF). These participants were randomized to once-weekly subcutaneous retatrutide (1, 4, 8, or 12 mg) or placebo for 48 weeks.

The authors reported concentration-dependent reductions in liver fat content. At 24 weeks, mean relative changes from baseline in liver fat were −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg), and −82.4% (12 mg), compared with +0.3% in the placebo arm [3]. Normal liver fat content (defined as <5%) was achieved at 24 weeks by 27%, 52%, 79%, and 86% of participants in the 1 mg, 4 mg, 8 mg, and 12 mg retatrutide arms respectively, compared with 0% of placebo participants.

Read the full study: Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease (Nature Medicine 2024).

Phase 1b Multi-escalating-amount Trial — Coskun et al., The Lancet (2022)

Coskun and colleagues conducted the foundational phase 1b, multicenter, double-blind, placebo-controlled, randomized, multi-escalating-amount trial of retatrutide in adults with type 2 diabetes. The 12-week trial assessed safety, tolerability, pharmacokinetics, and pharmacodynamics across an escalating amount-range, establishing the concentration-response profile that subsequently informed the phase 2 program.

The investigators reported concentration-dependent reductions in HbA1c and body weight, with a safety and tolerability profile broadly consistent with the GLP-1 receptor agonist class — primarily transient gastrointestinal events [4]. The pharmacokinetic data supported a circulatory half-life of approximately six days, consistent with a once-weekly administration interval.

Read the full study: LY3437943, a Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist in People with Type 2 Diabetes — A Phase 1b Trial (Lancet 2022).

About the Compound

Retatrutide is a synthetic, single-chain peptide that functions as an agonist at three incretin and glucagon receptors simultaneously: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. Based on cell-culture pharmacology studies, retatrutide is more potent at the human GIP receptor than endogenous ligands (by a factor of approximately 8.9) and slightly less potent at the GLP-1 and glucagon receptors (approximately 0.4 and 0.3 times as active as their endogenous ligands, respectively). The molecule is conjugated to a fatty diacid moiety that enables reversible binding to serum albumin, producing a circulatory half-life of approximately six days and supporting once-weekly subcutaneous administration in research models.

  • Development code: LY3437943
  • CAS Number: 2381089-83-2
  • Molecular Formula: C221H343N53O67
  • Molecular Weight: 4731.42 g/mol
  • Synonyms: Triple-G agonist, triple-hormone-receptor agonist (THR agonist)
  • Receptor targets (in research literature): GIP receptor, GLP-1 receptor, glucagon receptor (triple agonist)
  • Regulatory status (as of publication): Investigational; phase 3 trials ongoing. Not approved by the FDA, EMA, or any other regulatory authority for any indication.

Product Specifications

Omnix Peptides supplies retatrutide as a sterile, lyophilized (freeze-dried) powder in a sealed glass vial intended exclusively for in vitro laboratory research. Each production lot is independently characterized using high-performance liquid chromatography (HPLC) and liquid chromatography–mass spectrometry (LC–MS) protocols.

  • Format: Lyophilized powder
  • Available strengths: 5 mg · 10 mg · 15 mg · 20 mg · 30 mg · 40 mg · 50 mg per vial
  • Verified Purity: >99% (HPLC, LC–MS)
  • Container: Sterile, sealed glass vial
  • Documentation: Batch-specific Certificate of Analysis (COA) available

Storage, handling, intended-use, and regulatory information are provided in the corresponding tabs on this product page.

References

  1. Jastreboff AM, Kaplan LM, Frías JP, et al; Retatrutide Phase 2 Obesity Trial Investigators. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
  2. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. doi:10.1016/S0140-6736(23)01053-X
  3. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. doi:10.1038/s41591-024-03018-2
  4. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multi-escalating-amount trial. Lancet. 2022;400(10366):1869-1881. doi:10.1016/S0140-6736(22)02033-5

Related products

For research use only. Not for human consumption.